Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations

A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.

Related Keywords

United States ,American ,Alessandro Grandini ,J Womens Dermatol ,International Journal Of Women Dermatology ,Image Credit ,International Journal ,American Journal ,Managed Care ,Published February ,Published January ,Alopecia Areata ,Jaki Therapy ,